Home / Stocks / KYNB

Kyntra Bio (KYNB, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

Kyntra Bio (KYNB, Biotechnology) trades at a blended P/E of 1.1, about 489% above its historical normal valuation, with a forward growth estimate of -76.5%. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 0.2 on the same blended earnings, the 2026-09-18 close of $7.07 corresponds to about $1.20 a share. This is a valuation reference, not a price target.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-09-21
Blended P/E
1.1
Normal P/E
0.2
PEG
—
Fwd growth
-76.5%
Div yield
0.0%
RSI (14)
36.4
Neutral

The Street vs SeerForecast

Wall Street's mean price target for KYNB is $39.67 across 3 analysts, 447.1% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-08-07.

Blended P/E and rating by weekBlended P/E moved from 0.7 to 1.1 between 2026-08-07 and 2026-09-21, against a normal P/E of 0.2, with 0 rating changes over 16 recorded weeks.2026-08-07: P/E 0.7, Significantly overvalued (recalculated)2026-08-10: P/E 0.7, Significantly overvalued2026-08-14: P/E 0.7, Significantly overvalued (recalculated)2026-08-17: P/E 0.6, Significantly overvalued2026-08-21: P/E 0.6, Significantly overvalued (recalculated)2026-08-24: P/E 0.7, Significantly overvalued2026-08-27: P/E 0.7, Significantly overvalued (recalculated)2026-08-28: P/E 0.7, Significantly overvalued (recalculated)2026-08-30: P/E 0.7, Significantly overvalued (recalculated)2026-08-31: P/E 0.8, Significantly overvalued2026-09-05: P/E 0.8, Significantly overvalued (recalculated)2026-09-07: P/E 1.0, Significantly overvalued2026-09-12: P/E 1.0, Significantly overvalued (recalculated)2026-09-14: P/E 1.0, Significantly overvalued2026-09-19: P/E 1.0, Significantly overvalued (recalculated)2026-09-21: P/E 1.1, Significantly overvalued0.20.50.81.0Aug 7Aug 18Aug 29Sep 10Sep 21Normal P/E 0.2
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-07P/E 0.7+258%Significantly overvalued
2026-08-17P/E 0.6+211%Significantly overvalued
2026-09-21P/E 1.1+489%Significantly overvalued ← now

Frequently asked questions

Is Kyntra Bio stock overvalued?

At a blended P/E of 1.1 versus its historical normal P/E of 0.2, Kyntra Bio trades about 489% above its typical valuation. tickerseer currently rates it significantly overvalued.

What is Kyntra Bio's fair value and PEG?

Kyntra Bio trades at a blended P/E of 1.1 against a historical normal P/E of 0.2, a forward growth estimate of -76.5%. Priced at its historical normal P/E of 0.2 on the same blended earnings, the 2026-09-18 close of $7.07 corresponds to about $1.20 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Kyntra Bio changed?

tickerseer's rating has been significantly overvalued since 2026-08-07.

What is the analyst price target for Kyntra Bio?

The mean Wall Street price target for Kyntra Bio is $39.67 across 3 analysts, 447.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track KYNB free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.